NANALYSIS SCIENTIFIC CORP (NSCI.CA) Stock Fundamental Analysis
Canada - TSX-V:NSCI - CA63000Y1034 - Common Stock
0.195 CAD
0 (0%)
We assign a fundamental rating of 4 out of 10 to NSCI. NSCI was compared to 16 industry peers in the Health Care Equipment & Supplies industry. NSCI may be in some trouble as it scores bad on both profitability and health. A decent growth rate in combination with a cheap valuation! Better keep an eye on NSCI.
1. Profitability
1.1 Basic Checks
In the past year NSCI has reported negative net income.
In the past year NSCI had a positive cash flow from operations.
In the past 5 years NSCI always reported negative net income.
In the past 5 years NSCI reported 4 times negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of -33.34%, NSCI belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
The Return On Equity of NSCI (-99.08%) is better than 81.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.34% | ||
| ROE | -99.08% | ||
| ROIC | N/A |
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 28.40%, NSCI is doing worse than 62.50% of the companies in the same industry.
In the last couple of years the Gross Margin of NSCI has declined.
NSCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
2. Health
2.1 Basic Checks
NSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
NSCI has more shares outstanding than it did 1 year ago.
NSCI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NSCI is higher compared to a year ago.
2.2 Solvency
NSCI has an Altman-Z score of -0.64. This is a bad value and indicates that NSCI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.64, NSCI is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
The Debt to FCF ratio of NSCI is 352.74, which is on the high side as it means it would take NSCI, 352.74 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 352.74, NSCI belongs to the best of the industry, outperforming 93.75% of the companies in the same industry.
NSCI has a Debt/Equity ratio of 0.72. This is a neutral value indicating NSCI is somewhat dependend on debt financing.
NSCI has a better Debt to Equity ratio (0.72) than 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | 352.74 | ||
| Altman-Z | -0.64 |
ROIC/WACCN/A
WACC5.95%
2.3 Liquidity
A Current Ratio of 0.87 indicates that NSCI may have some problems paying its short term obligations.
NSCI has a better Current ratio (0.87) than 62.50% of its industry peers.
NSCI has a Quick Ratio of 0.87. This is a bad value and indicates that NSCI is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of NSCI (0.61) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.87 | ||
| Quick Ratio | 0.61 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.12% over the past year.
Looking at the last year, NSCI shows a quite strong growth in Revenue. The Revenue has grown by 9.01% in the last year.
NSCI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 40.32% yearly.
EPS 1Y (TTM)13.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.65%
Revenue 1Y (TTM)9.01%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-16.54%
3.2 Future
Based on estimates for the next years, NSCI will show a very strong growth in Earnings Per Share. The EPS will grow by 34.28% on average per year.
NSCI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.55% yearly.
EPS Next Y81.82%
EPS Next 2Y65.14%
EPS Next 3Y45.9%
EPS Next 5Y34.28%
Revenue Next Year-0.13%
Revenue Next 2Y5.27%
Revenue Next 3Y5.73%
Revenue Next 5Y5.55%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
NSCI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 4.83, which indicates a rather cheap valuation of NSCI.
NSCI's Price/Forward Earnings ratio is rather cheap when compared to the industry. NSCI is cheaper than 100.00% of the companies in the same industry.
NSCI's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.89.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.83 |
4.2 Price Multiples
NSCI's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NSCI is cheaper than 93.75% of the companies in the same industry.
93.75% of the companies in the same industry are more expensive than NSCI, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 447.8 | ||
| EV/EBITDA | 52.9 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NSCI's earnings are expected to grow with 45.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.14%
EPS Next 3Y45.9%
5. Dividend
5.1 Amount
No dividends for NSCI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:NSCI (9/26/2025, 7:00:00 PM)
0.195
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners8.54%
Inst Owner ChangeN/A
Ins Owners3.96%
Ins Owner ChangeN/A
Market Cap22.39M
Analysts80
Price Target0.84 (330.77%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-98.02%
Min EPS beat(2)-98.02%
Max EPS beat(2)-98.02%
EPS beat(4)0
Avg EPS beat(4)-98.02%
Min EPS beat(4)-98.02%
Max EPS beat(4)-98.02%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.55%
Min Revenue beat(2)-7.95%
Max Revenue beat(2)-7.14%
Revenue beat(4)2
Avg Revenue beat(4)2.32%
Min Revenue beat(4)-7.95%
Max Revenue beat(4)16.28%
Revenue beat(8)5
Avg Revenue beat(8)11.79%
Revenue beat(12)7
Avg Revenue beat(12)5.02%
Revenue beat(16)8
Avg Revenue beat(16)1.86%
PT rev (1m)0%
PT rev (3m)-13.16%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.74%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.83 | ||
| P/S | 0.52 | ||
| P/FCF | 447.8 | ||
| P/OCF | 12.07 | ||
| P/B | 1.77 | ||
| P/tB | N/A | ||
| EV/EBITDA | 52.9 |
EPS(TTM)-0.06
EYN/A
EPS(NY)0.04
Fwd EY20.72%
FCF(TTM)0
FCFY0.22%
OCF(TTM)0.02
OCFY8.28%
SpS0.37
BVpS0.11
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.34% | ||
| ROE | -99.08% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.4% | ||
| FCFM | 0.12% |
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
F-Score5
Asset Turnover1.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | 352.74 | ||
| Debt/EBITDA | 12.75 | ||
| Cap/Depr | 42.03% | ||
| Cap/Sales | 4.19% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 261.64% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.87 | ||
| Quick Ratio | 0.61 | ||
| Altman-Z | -0.64 |
F-Score5
WACC5.95%
ROIC/WACCN/A
Cap/Depr(3y)97.82%
Cap/Depr(5y)114.88%
Cap/Sales(3y)16.41%
Cap/Sales(5y)20.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.65%
EPS Next Y81.82%
EPS Next 2Y65.14%
EPS Next 3Y45.9%
EPS Next 5Y34.28%
Revenue 1Y (TTM)9.01%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-16.54%
Revenue Next Year-0.13%
Revenue Next 2Y5.27%
Revenue Next 3Y5.73%
Revenue Next 5Y5.55%
EBIT growth 1Y52.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year253.78%
EBIT Next 3Y72.2%
EBIT Next 5Y52.33%
FCF growth 1Y100.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y113.25%
OCF growth 3YN/A
OCF growth 5Y33.1%